Risk of serious infection

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Anti-TNF therapy is effective for inducing and maintaining remission in both pediatric Crohn's disease and ulcerative colitis patients; however, adverse effects, such as serious infection and lymphoma, are of concern. A recent study has indicated that anti-TNFa therapy in patients aged ≥ 50 years is associated with significantly increased rates of serious infections; therefore, physicians should pay careful attention to detect the development of infections in elderly patients treated with this therapy. Patients with inflammatory bowel disease (IBD) should be considered for the five following vaccines: the varicella zoster, human papillomavirus, influenza, hepatitis B, and pneumococcal vaccines. Because IBD patients often fail to recognize whether they have previously had a vaccinepreventive illness, such as varicella zoster virus infection, antibodies for varicella zoster virus should be measured as early as possible after diagnosis of IBD, and vaccination might be considered for patients who do not have antibodies before anti-TNFa agents are used.

Original languageEnglish
Title of host publicationAnti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
PublisherS. Karger AG
Pages147-151
Number of pages5
ISBN (Print)9783318054743, 9783318054736
DOIs
Publication statusPublished - 2015 Jul 9

Fingerprint

Viruses
Chickenpox Vaccine
Hepatitis B Vaccines
Pneumococcal Vaccines
Pediatrics
Anti-Idiotypic Antibodies
Antibodies

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Naganuma, M. (2015). Risk of serious infection. In Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease (pp. 147-151). S. Karger AG. https://doi.org/10.1159/000381595

Risk of serious infection. / Naganuma, Makoto.

Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. S. Karger AG, 2015. p. 147-151.

Research output: Chapter in Book/Report/Conference proceedingChapter

Naganuma, M 2015, Risk of serious infection. in Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. S. Karger AG, pp. 147-151. https://doi.org/10.1159/000381595
Naganuma M. Risk of serious infection. In Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. S. Karger AG. 2015. p. 147-151 https://doi.org/10.1159/000381595
Naganuma, Makoto. / Risk of serious infection. Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. S. Karger AG, 2015. pp. 147-151
@inbook{4ca78993ffed497c8d5430fd76f4ff38,
title = "Risk of serious infection",
abstract = "Anti-TNF therapy is effective for inducing and maintaining remission in both pediatric Crohn's disease and ulcerative colitis patients; however, adverse effects, such as serious infection and lymphoma, are of concern. A recent study has indicated that anti-TNFa therapy in patients aged ≥ 50 years is associated with significantly increased rates of serious infections; therefore, physicians should pay careful attention to detect the development of infections in elderly patients treated with this therapy. Patients with inflammatory bowel disease (IBD) should be considered for the five following vaccines: the varicella zoster, human papillomavirus, influenza, hepatitis B, and pneumococcal vaccines. Because IBD patients often fail to recognize whether they have previously had a vaccinepreventive illness, such as varicella zoster virus infection, antibodies for varicella zoster virus should be measured as early as possible after diagnosis of IBD, and vaccination might be considered for patients who do not have antibodies before anti-TNFa agents are used.",
author = "Makoto Naganuma",
year = "2015",
month = "7",
day = "9",
doi = "10.1159/000381595",
language = "English",
isbn = "9783318054743",
pages = "147--151",
booktitle = "Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease",
publisher = "S. Karger AG",

}

TY - CHAP

T1 - Risk of serious infection

AU - Naganuma, Makoto

PY - 2015/7/9

Y1 - 2015/7/9

N2 - Anti-TNF therapy is effective for inducing and maintaining remission in both pediatric Crohn's disease and ulcerative colitis patients; however, adverse effects, such as serious infection and lymphoma, are of concern. A recent study has indicated that anti-TNFa therapy in patients aged ≥ 50 years is associated with significantly increased rates of serious infections; therefore, physicians should pay careful attention to detect the development of infections in elderly patients treated with this therapy. Patients with inflammatory bowel disease (IBD) should be considered for the five following vaccines: the varicella zoster, human papillomavirus, influenza, hepatitis B, and pneumococcal vaccines. Because IBD patients often fail to recognize whether they have previously had a vaccinepreventive illness, such as varicella zoster virus infection, antibodies for varicella zoster virus should be measured as early as possible after diagnosis of IBD, and vaccination might be considered for patients who do not have antibodies before anti-TNFa agents are used.

AB - Anti-TNF therapy is effective for inducing and maintaining remission in both pediatric Crohn's disease and ulcerative colitis patients; however, adverse effects, such as serious infection and lymphoma, are of concern. A recent study has indicated that anti-TNFa therapy in patients aged ≥ 50 years is associated with significantly increased rates of serious infections; therefore, physicians should pay careful attention to detect the development of infections in elderly patients treated with this therapy. Patients with inflammatory bowel disease (IBD) should be considered for the five following vaccines: the varicella zoster, human papillomavirus, influenza, hepatitis B, and pneumococcal vaccines. Because IBD patients often fail to recognize whether they have previously had a vaccinepreventive illness, such as varicella zoster virus infection, antibodies for varicella zoster virus should be measured as early as possible after diagnosis of IBD, and vaccination might be considered for patients who do not have antibodies before anti-TNFa agents are used.

UR - http://www.scopus.com/inward/record.url?scp=84960236160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960236160&partnerID=8YFLogxK

U2 - 10.1159/000381595

DO - 10.1159/000381595

M3 - Chapter

AN - SCOPUS:84960236160

SN - 9783318054743

SN - 9783318054736

SP - 147

EP - 151

BT - Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

PB - S. Karger AG

ER -